tetano
Editor, Senior Moderator
J Int Med Res
. 2022 Mar;50(3):3000605221086155.
doi: 10.1177/03000605221086155.
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L Seneviratne[SUP] 1 [/SUP], Pamodh Yasawardene[SUP] 2 [/SUP], Widuranga Wijerathne[SUP] 2 [/SUP], Buddhika Somawardana[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected over 220 million individuals worldwide, and has been shown to cause increased disease severity and mortality in patients with active cancer versus healthy individuals. Vaccination is important in reducing COVID-19-associated morbidity and mortality. Thus, the aim of this article was to review the existing knowledge on effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer. Fifty-four articles were included following a search of PubMed and Google Scholar databases for studies published between January 2020 and September 2021 that investigated humoral and cell-mediated immune responses following COVID-19 vaccination in patients with cancer. Immunogenicity of vaccines was found to be lower in patients with cancer versus healthy individuals, and humoral immune responses were inferior in those with haematological versus solid cancers. Patient-, disease-, and treatment-related factors associated with poorer vaccine responses should be identified and corrected or mitigated when possible. Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. Vaccine adverse effect profiles are comparable between patients with cancer and healthy individuals.
Keywords: COVID-19; cancer; haematological malignancies; solid malignancies; vaccine effectiveness; vaccine safety; vaccines.
. 2022 Mar;50(3):3000605221086155.
doi: 10.1177/03000605221086155.
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L Seneviratne[SUP] 1 [/SUP], Pamodh Yasawardene[SUP] 2 [/SUP], Widuranga Wijerathne[SUP] 2 [/SUP], Buddhika Somawardana[SUP] 3 [/SUP]
Affiliations
- PMID: 35313761
- DOI: 10.1177/03000605221086155
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected over 220 million individuals worldwide, and has been shown to cause increased disease severity and mortality in patients with active cancer versus healthy individuals. Vaccination is important in reducing COVID-19-associated morbidity and mortality. Thus, the aim of this article was to review the existing knowledge on effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer. Fifty-four articles were included following a search of PubMed and Google Scholar databases for studies published between January 2020 and September 2021 that investigated humoral and cell-mediated immune responses following COVID-19 vaccination in patients with cancer. Immunogenicity of vaccines was found to be lower in patients with cancer versus healthy individuals, and humoral immune responses were inferior in those with haematological versus solid cancers. Patient-, disease-, and treatment-related factors associated with poorer vaccine responses should be identified and corrected or mitigated when possible. Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. Vaccine adverse effect profiles are comparable between patients with cancer and healthy individuals.
Keywords: COVID-19; cancer; haematological malignancies; solid malignancies; vaccine effectiveness; vaccine safety; vaccines.